These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1383408)

  • 1. Vaccination by cholera toxin conjugated to a herpes simplex virus type 2 glycoprotein D peptide.
    Drew MD; Estrada-Correa A; Underdown BJ; McDermott MR
    J Gen Virol; 1992 Sep; 73 ( Pt 9)():2357-66. PubMed ID: 1383408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholera toxin conjugates for intragastric vaccination against herpes simplex virus type 2.
    Drew MD; Estrada AE; Underdown BJ; McDermott MR
    Reg Immunol; 1992; 4(2):79-85. PubMed ID: 1503890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88.
    Tengvall S; O'Hagan D; Harandi AM
    Antiviral Res; 2008 Jun; 78(3):202-14. PubMed ID: 18276020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
    Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
    Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic glycoprotein D-related peptides protect mice against herpes simplex virus challenge.
    Eisenberg RJ; Cerini CP; Heilman CJ; Joseph AD; Dietzschold B; Golub E; Long D; Ponce de Leon M; Cohen GH
    J Virol; 1985 Dec; 56(3):1014-7. PubMed ID: 2999419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
    Karem KL; Bowen J; Kuklin N; Rouse BT
    J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional T cell recognition of synthetic peptides corresponding to continuous antibody epitopes of herpes simplex virus type 1 glycoprotein D.
    Wyckoff JH; Osmand AP; Eisenberg RJ; Cohen GH; Rouse BT
    Immunobiology; 1988 May; 177(2):134-48. PubMed ID: 2456985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines.
    Bettahi I; Nesburn AB; Yoon S; Zhang X; Mohebbi A; Sue V; Vanderberg A; Wechsler SL; BenMohamed L
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4643-53. PubMed ID: 17898288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baculovirus-expressed glycoprotein H of herpes simplex virus type 1 (HSV-1) induces neutralizing antibody and delayed type hypersensitivity responses, but does not protect immunized mice against lethal HSV-1 challenge.
    Ghiasi H; Kaiwar R; Nesburn AB; Wechsler SL
    J Gen Virol; 1992 Mar; 73 ( Pt 3)():719-22. PubMed ID: 1312127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus neutralizing activity induced by synthetic peptides of glycoprotein D of herpes simplex virus type 1, selected by their reactivity with hyperimmune sera from mice.
    Geerligs HJ; Kocken CH; Drijfhout JW; Weijer WJ; Bloemhoff W; Wilterdink JB; Welling GW; Welling-Wester S
    J Gen Virol; 1990 Aug; 71 ( Pt 8)():1767-74. PubMed ID: 2167930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
    Aurelian L; Smith CC; Wachsman M; Paoletti E
    Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.
    Rooney JF; Wohlenberg C; Cremer KJ; Moss B; Notkins AL
    J Virol; 1988 May; 62(5):1530-4. PubMed ID: 2833606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
    Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
    Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitope mapping of the 273-284 region of HSV glycoprotein D by synthetic branched polypeptide carrier conjugates.
    Hudecz F; Hilbert A; Mezö G; Mucsi I; Kajtár J; Bösze S; Kurucz I; Rajnavölgyi E
    Pept Res; 1993; 6(5):263-71. PubMed ID: 7504960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal and systemic antiviral antibodies in mice inoculated intravaginally with herpes simplex virus type 2.
    McDermott MR; Brais LJ; Evelegh MJ
    J Gen Virol; 1990 Jul; 71 ( Pt 7)():1497-504. PubMed ID: 2165134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal immunization against herpes simplex virus infection by using a recombinant glycoprotein D fused with immunomodulating proteins, the B subunit of Escherichia coli heat-labile enterotoxin and interleukin-2.
    Hazama M; Mayumi-Aono A; Miyazaki T; Hinuma S; Fujisawa Y
    Immunology; 1993 Apr; 78(4):643-9. PubMed ID: 8388365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunisation against HSV-1 keratitis with a synthetic gD peptide.
    Heiligenhaus A; Wells PA; Foster CS
    Eye (Lond); 1995; 9 ( Pt 1)():89-95. PubMed ID: 7713256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of potent protection against acute and latent herpes simplex virus infection in mice vaccinated with dendritic cells.
    Ghasemi M; Erturk M; Buruk K; Sonmez M
    Cytotherapy; 2013 Mar; 15(3):352-61. PubMed ID: 23579060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2.
    Quenelle DC; Collins DJ; Marciani DJ; Kern ER
    Vaccine; 2006 Mar; 24(10):1515-22. PubMed ID: 16288820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Live vaccinia virus recombinants expressing herpes simplex virus genes.
    Rooney JF; Wohlenberg CR; Moss B; Notkins AL
    Rev Infect Dis; 1991; 13 Suppl 11():S898-903. PubMed ID: 1664124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.